180 related articles for article (PubMed ID: 34298439)
1. Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.
Wu Y; Ni H; Yang D; Niu Y; Chen K; Xu J; Wang F; Tang S; Shi Y; Zhang H; Hu J; Xia D; Wu Y
Pathol Res Pract; 2021 Aug; 224():153551. PubMed ID: 34298439
[TBL] [Abstract][Full Text] [Related]
2. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
3. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
[TBL] [Abstract][Full Text] [Related]
5. ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria.
Djambazov SN; Vekov TY; Mekov EV; Slavchev GS; Petkov RE; Kostadinov DT; Konteva LT
Folia Med (Plovdiv); 2018 Sep; 60(3):397-401. PubMed ID: 30355843
[TBL] [Abstract][Full Text] [Related]
6. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
8. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
9. Two different patterns of lung adenocarcinoma with concomitant
Zhao D; Fan J; Peng L; Huang B; Zhu Y; Shi H; Dai X; Nie X
Tumori; 2022 Feb; 108(1):12-18. PubMed ID: 33818198
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
[TBL] [Abstract][Full Text] [Related]
12. Imaging Features and Metastatic Patterns of Advanced
Mendoza DP; Lin JJ; Rooney MM; Chen T; Sequist LV; Shaw AT; Digumarthy SR
AJR Am J Roentgenol; 2020 Apr; 214(4):766-774. PubMed ID: 31887093
[No Abstract] [Full Text] [Related]
13. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.
Fan J; Wu J; Huang B; Zhu Y; Shi H; Dai X; Nie X
Diagn Pathol; 2020 May; 15(1):42. PubMed ID: 32375829
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L; Lei J; Wang QZ; Li J; Wu L
Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
18. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
19. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
